Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00004)
| Name |
Endotheliitis
|
||||
|---|---|---|---|---|---|
| ICD |
ICD-11: 1F00
|
||||
Full List of Target(s) of This Ferroptosis-centered Disease
Unspecific Target
| In total 2 item(s) under this target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | |||
| Responsed Disease | Endotheliitis [ICD-11: 1F00] | |||
| Responsed Regulator | hsa-miR-30e-5p (miRNA) | Suppressor | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| AMPK signaling pathway | hsa04152 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | hEPCs (Endothelial progenitor cells) | |||
| HUVECs (Human umbilical vein endothelial cells) | ||||
| Response regulation | EPCs-Exos inhibited Erastin-induced HUVEC ferroptosis and endothelial injury. EPCs-Exos promoted the activation of the AMPK pathway by upregulating the expression of miR-30e-5p in HUVECs and inhibiting the expression of SP1 in HUVECs, thus inhibiting Erastin-induced cell ferroptosis. | |||
| Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | |||
| Responsed Disease | Endotheliitis [ICD-11: 1F00] | |||
| Responsed Regulator | Transcription factor Sp1 (SP1) | Driver | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| AMPK signaling pathway | hsa04152 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | hEPCs (Endothelial progenitor cells) | |||
| HUVECs (Human umbilical vein endothelial cells) | ||||
| Response regulation | EPCs-Exos inhibited Erastin-induced HUVEC ferroptosis and endothelial injury. EPCs-Exos promoted the activation of the AMPK pathway by upregulating the expression of miR-30e-5p in HUVECs and inhibiting the expression of SP1 in HUVECs, thus inhibiting Erastin-induced cell ferroptosis. | |||
References